Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
Oramed Pharmaceuticals has been downgraded from 'Strong Buy' to 'Hold' following the failure of its phase 3 trial for the oral insulin drug ORMD-0801. The company is now pivoting towards new strategic investment directions. This shift comes as Oramed reassesses its approach in light of recent setbacks in its drug development pipeline.
- ▪Oramed Pharmaceuticals' ORMD-0801 failed in a phase 3 trial for Type 2 Diabetes.
- ▪The company's stock rating has been downgraded to 'Hold'.
- ▪Oramed is exploring new strategic investment directions following the trial failure.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908089-oramed-pharmaceuticals-oral-insulin-drug-failure-pivot-and-new-strategic-investment-direction"},"author":{"@type":"Person","name":"Terry…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
